Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Genistein and Doxorubicin Hydrochloride

Research Papers that Mention the Interaction

Genistein also shows synergistic behavior with well-known anticancer drugs, such as adriamycin , docetaxel, and tamoxifen, suggesting a potential role in combination therapy.
Advances in nutrition  •  2015  |  View Paper
Altogether this study highlights the potential role of … in targeting HSPG receptors and synergistic delivery of Dox … Gen as a promising strategy to effectively inhibit BAC progression and these findings could open a new window to deliver combinations of chemotherapeutic agents along with anti-angiogenic ligands using hybrid nanoparticles.
Biomaterials science  •  2020  |  View Paper
Consistent with previous reports, genistein combined with doxorubicin had a synergistic effect on MCF-7/Adr cells, and genistein reduced the chemoresistance of these cells.
Genistein treatment increased the intracellular accumulation of doxorubicin but did not influence P-gp function.
The combination of genistein and doxorubicin significantly induced cell cycle arrest and apoptosis.
Therefore, our results demonstrated that genistein combined with doxorubicin had a synergistic effect on MCF-7/Adr cells, and the mechanisms likely involve an increase in the intracellular accumulation of doxorubicin and suppression of HER2/neu expression.
Oncology reports  •  2014  |  View Paper
Collectively, our results clearly suggest that genistein pretreatment inactivates NF-kappaB and may contribute to increased growth inhibition and apoptosis induced by cisplatin, docetaxel, and doxorubicin in prostate, breast, lung, and pancreatic cancer cells.
Cancer research  •  2005  |  View Paper
Genistein enhanced cytotoxic effect of ADR at low doses less than IC50 against the human breast cancer cell.
These results suggest that genistein enhances necrotic-like cell death of the breast cancer cells through the inactivation of HER-2 receptor and Akt in combination with ADR.
Research communications in molecular pathology and pharmacology  •  2003  |  View Paper
Combinations of genistein or tyrphostin AG 1478 with cisplatin, doxorubicin , or etoposide enhanced the antiproliferative effects and induced programmed cell death in NCI-H596 cells, whereas no such additive effects were observed in NCI-H358 cells.
Anticancer research  •  1999  |  View Paper
The tyrosine kinase inhibitor genistein was a potent blocker of doxorubicin efflux in the PSN1/ADR cells but showed no activity in the H134 AD cells.
British Journal of Cancer  •  1996  |  View Paper
Although the amount of ADM was decreased in the nuclei of K562/TPA cells, it was significantly increased after incubation in the presence of genistein.
International journal of cancer  •  1994  |  View Paper
Three inhibitors of tyrosine kinases genistein , kaempferol, and quercetin) can inhibit the in vitro generation of ADR activity.
Experimental cell research  •  1993  |  View Paper
Genistein enhanced the Nrf2 and HO-1 expression, which showed protection against oxidative insult induced by Dox.
Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer  •  2019  |  View Paper